|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Dimension Therapeutics
| | | Phone: | (617) 401-0011 | Year Established: | 2013 | Ticker: | DMTX | Exchange: | NASDAQ | Main Contact: | Annalisa Jenkins, MBBS, FRCP, CEO | | Other Contacts: | Khandan Baradaran, Ph.D., Head of Quality Andy Hu, MD, MBA, Head of Business Development Stephanie Haller, Head of Clinical Operations Mary Thistle, COO Eric Crombez, MD, CMO K. Reed Clark, Ph.D., Head of Pharmaceutical Development Janet Rae, RAC, Head of Global Regulatory Affairs Deborah Geraghty, Ph.D., MBA, Head of Commercial and Portfolio Strategy Sam Wadsworth, Ph.D., CSO
| | Company Description | Dimension Therapeutics, a wholly-owned subsidiary of Ultragenyx, is a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, and a collaboration with Bayer in hemophilia A. Dimension has initiated a phase 1/2 clinical trial with DTX301 for the treatment of OTC deficiency. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers.
On Nov. 7, 2017, Ultragenyx announced successful completion of its acquisition of Dimension Therapeutics. Ultragenyx completed its previously announced tender offer to purchase all outstanding shares of common stock of Dimension for $6.00 per share in cash, without interest, or $152.3 million in cash.
Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The Company has rapidly built and advanced a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. | |
|
|
|